Table 1 Activated mammalian target of rapamycin (p-mTOR) expression and clinicopathological characteristics of 105 patients with oesophageal squamous cell carcinoma
CharacteristicNo. of cases (%)*p-mTOR (%)*p Value†
+++
Age (years)
    ⩾6254 (51)43 (80)9 (17)2 (4)
    <6251 (49)36 (71)9 (18)6 (12)0.37
Gender
    Male56 (53)42 (75)9 (16)5 (9)
    Female49 (47)37 (76)9 (18)3 (6)1.00
Tumour location
    Upper 1/3 oesophagus9 (9)7 (78)2 (22)0 (0)
    Middle 1/3 oesophagus55 (52)41 (75)10 (18)4 (7)
    Distal 1/3 oesophagus41 (39)31 (76)6 (15)4 (10)1.00
Differentiation grade‡
    G16 (6)5 (83)0 (0)1 (17)
    G265 (62)54 (83)9 (14)2 (3)
    G334 (32)20 (59)9 (26)5 (15)0.024
TNM stage
    I7 (7)4 (57)1 (14)2 (29)
    IIa28 (27)23 (82)4 (14)1 (4)
    IIb7 (7)4 (57)1 (14)2 (29)
    III48 (46)36 (75)11 (23)1 (2)
    IVa6 (6)5 (83)0 (0)1 (17)
    IVb9 (9)7 (78)1 (11)1 (11)0.62
Lymph node metastasis (N1 and M1 lymph nodes)
    No43 (41)31 (72)8 (19)4 (9)
    Yes62 (59)48 (77)10 (16)4 (6)0.65
Extracapsular growth¶
    No28 (45)22 (79)5 (18)1 (4)
    Yes34 (55)26 (76)5 (15)3 (9)1.00
Ki-67 score§
    <10%5 (5)3 (60)1 (20)1 (20)
    10–50%85 (83)66 (78)14 (16)5 (6)
    >50%13 (13)8 (62)3 (23)2 (15)0.26
Total105 (100)79 (75)18 (17)8 (8)
  • *Sum of percentages may exceed 100% because of rounding.

  • †Calculated between p-mTOR positive (score + and ++) and p-mTOR negative (score −) tumours.

  • ‡G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.

  • ¶Calculated for the 62 patients with lymph node metastases.

  • §For comparison of p-mTOR expression and Ki-67 expression, two extra cases were excluded from the study population since the tumour cores of these cases were absent on the TMA slide stained for Ki-67.

  • TMN, tumour, node, metastases.